REDWOOD CITY, Calif., Feb 11, 2026 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency.

Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “The need for proactive chronic care management has never been greater. We’re proud to deliver our third consecutive quarter of positive EBITDA and net operating income, which reflects continued revenue growth, sustained margins, and disciplined operational execution. Over the next 30 years, cardiovascular disease is projected to impact over 60% of the population. This represents nearly $1.8 trillion in costs, even though up to 80% of cases are preventable with early intervention. We believe this underscores the urgent need to shift care from reactive treatment to proactive monitoring.

Biotricity is helping lead that transition by bringing clinical-grade, easy-to-use diagnostic solutions out of episodic care settings and into everyday life, where most meaningful health events occur. Our approach allows providers to extend care beyond traditional touchpoints so they can serve more patients and improve outcomes without adding additional workload. The strength of this model is reflected in our rapidly expanding digital ecosystem and high customer retention of 90+%. In just 2 years our app base has scaled from 4,500 to more than 44,000 users, and our network of over 2,500 providers that support 4,000,000 patients annually continues to grow.

Importantly, we’re on track to obtain FDA clearance for our groundbreaking AI clinical model in the coming months. Our Cardiac AI Cloud platform leverages more than two trillion anonymized heartbeats to enhance diagnostic accuracy, improving throughput. Combined with our automation and operational AI capabilities, our technologies enable us to scale efficiently and pass those efficiencies on to our customers. The result is higher-quality care, more patients served, and increased revenue opportunities for medical facilities, creating meaningful value across the care continuum with both providers and patients winning. By facilitating this, Biotricity is positioned for sustainable, long-term growth as customer satisfaction drives adoption and expansion, allowing us to continue to revolutionize the cardiac care landscape.”

Q3-FY26 Financial Highlights

• Revenue increased 10.2% to $4 million from $3.6 million in the corresponding prior year period
• Gross margin was 81.5% for the three months ended December 31, 2025, as compared to 76.4% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure.
• Net loss decreased to $1.1 million, or $0.042 per share, from a net loss of $1.3 million, or $0.054 per share; this was a 13% improvement from the corresponding prior year quarter.

Operating Highlights for Q3-FY26 and the Future

• Q3-FY26 recurring (TaaS) Technology Fees rose a robust 7.4% from the corresponding prior year period to $3.6 million, representing 91.2% of total revenue for Q3-FY26
• The Company maintained its track record of strong customer retention, supported by the quality of its solutions, best-in-class customer support, and accuracy and ease-of-use of its diagnostic technology.
• With approvals in Canada, Saudi Arabia, and Argentina, the Company continued to advance strategic regulatory approvals across international markets, laying the foundation for distribution partnerships.
• Leveraging its seasoned sales force and strategic partnerships, the Company continued to expand its footprint across broader national markets, with penetration across thousands of cardiologists in hundreds of centers.

Full details of the Company’s financial results will be filed with the SEC on Form 10-K and available by visiting www.sec.gov.

Financial Results and Business Update Conference Call

Management will host a conference call on Wednesday, February 11th, 2026 at 4:30 p.m. ET to discuss its financial results for fiscal third quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://biotricity.com/investors/

Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call
Date: Wednesday February 11^th, 2026
Time: 4:30pm ET (1:30pm PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1751341&tp_key=10b4deecf5

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.

A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.

Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13758520
Expiration: Wednesday February 25, 2026 at 11:59 PM ET

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com

REDWOOD CITY, Calif., Feb 05, 2026 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11^th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity’s Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.

Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call
Date: Wednesday, February 11, 2026
Time: 4:30 PM ET (1:30 PM PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1751341&tp_key=10b4deecf5

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.

A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.

Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13758520
Expiration: Wednesday, February 25, 2026 at 11:59 PM ET

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com

REDWOOD CITY, Calif., Nov 14, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth.

Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “This quarter demonstrates the scalability and strength of our model as we continue to sharpen operational efficiency through proprietary AI-driven automation to maintain margins and accelerate growth. These efforts have strengthened our commercial execution and positioned us to capture the rising demand across the cardiac monitoring landscape.”

The rapid adoption of our next-generation cardiac monitoring device, Biocore Pro, and the launch of large-scale cardiac monitoring pilots across leading hospital networks validate our ability to scale both technology and impact. Building on this momentum, we are extending our reach into international markets to increase accessibility and strengthen our global footprint, expanding the availability of advanced cardiac diagnostics worldwide. At the same time, our strategic entry into adjacent fields such as sleep and pulmonology continues to diversify our portfolio and reinforce Biotricity’s position as a leader in connected healthcare. Our focus is to deliver a comprehensive suite of diagnostic tools that empower clinicians with deeper, more accessible insights for preventive and precision care.”

Q2-FY26 Financial Highlights

• Revenue increased 19% to $3.9 million from $3.3 million in the corresponding prior year period
• Gross margin was 81.9% for the three months ended June 30, 2025, as compared to 75.3% in the corresponding prior year quarter. This reflects the expansion of our recurring technology fee revenue base, efficiency gains from proprietary AI-driven operational automation, and ongoing improvements in monitoring and cloud cost structure.
• Net loss decreased to $0.77 million, or $0.03 per share, from a net loss of $1.7 million, or $0.07 per share; this was a 53.3% improvement from the corresponding prior year quarter.

Operating Highlights for Q2-FY26 and the Future

• Q2-FY26 recurring (TaaS) Technology Fees rose a robust 4.2% from the corresponding prior year period, to $3.5 million, representing 88.7% of total revenue for Q2-FY26
• The Company sustained its record of strong customer retention, driven by high-quality, cardiologist- and patient-friendly services that prioritize diagnostic accuracy and ease of use.
• The Company made meaningful progress in securing regulatory approval across key international markets, including Canada, Saudi Arabia, and Argentia, laying the foundation for broader distribution in the coming years.
• The Company continued expanding its U.S. market presence, with penetration across thousands of cardiologists in hundreds of centers, though a combination of direct sales force efforts and strategic alliances with three of the top GPOs that collectively represent 90% of U.S. hospitals.

Full details of the Company’s financial results will be filed with the SEC on Form 10-K and available by visiting www.sec.gov.

Financial Results and Business Update Conference Call

Management will host a conference call on Friday, November 14th, 2025 at 4:30 p.m. ET to discuss its financial results for fiscal second quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://biotricity.com/investors/

Event: Biotricity Fiscal 2026 Second Quarter Financial Results and Business Update Call
Date: Friday, November 14^th, 2025
Time: 4:30pm ET (1:30pm PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1740411&tp_key=f4feb0c9ef

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.

A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.

Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13756814
Expiration: Friday, November 28, 2025 at 11:50 PM ET

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com

REDWOOD CITY, Calif., Nov 07, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th, 2025 at 4:30 PM Eastern Time. The Company announces continued strength and progress in financial performance. Biotricity’s Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.

Event: Biotricity Fiscal 2026 Second Quarter Financial Results and Business Update Call
Date: Friday, November 14th, 2025
Time: 4:30 PM ET (1:30 PM PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1740411&tp_key=f4feb0c9ef

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.

A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.

Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13756814
Expiration: Friday, November 28, 2025 at 11:50 PM ET

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com

In this blog, we will examine the differences between 2 cardiac monitoring solutions, the Spider Heart Monitor and Biotricity’s Biocore Pro. Let’s look at how they compare and show you how Biocore Pro is better suited for your heart monitoring needs.

What Is the Spider Heart Monitor?

The Spider Heart Monitor is a compact, wearable ECG device designed for outpatient heart monitoring. The Spider Heart Monitor attaches to the chest and provides continuous recording of heart activity. The Spider Heart Monitor is useful for patients who require prolonged outpatient monitoring, such as those with arrhythmias or other cardiac conditions. Below are the Spider Heart Monitor device’s highlighted features:

1. Compact Design: Small and lightweight, the Spider Heart Monitor is suitable for long-term use.
2. Continuous Monitoring: Ensures consistent heart activity tracking.
3. Connectivity: Enables remote monitoring by sending data to healthcare providers.

Introducing Biotricity’s Biocore Pro

Biotricity’s Biocore Pro is a cutting-edge, connected 3-lead cardiac patch monitor designed for continuous heart monitoring with clinical-grade accuracy. Like the Spider Heart Monitor, Biocore Pro is useful for patients who require prolonged outpatient monitoring, such as those with arrhythmias or other cardiac conditions. Designed with both patients and healthcare providers in mind, Biocore Pro’s compact, wireless form ensures comfort without compromising on performance. What sets Biocore Pro apart is its ability to deliver detailed, multi-lead data while offering 24/7 accessibility to healthcare providers for continuous heart monitoring over extended periods. Seamlessly integrated with BIotricity’s platform, Biocare Diagnostics, and Biocore Pro enables comprehensive care and rapid intervention when needed. Key features that distinguish Biocore Pro include:

1. 3-Lead Monitoring: Offers a comprehensive view of heart activity, capturing more detailed information compared to single-lead or 2-lead monitors.
2. Comfortable for Long-Term Wear: Engineered for continuous use without disrupting daily routines.
3. Advanced Analytics: Provides in-depth insights into heart health, aiding in the detection of potential issues.
4. Long Battery Life: Designed for extended use, ensuring continuous monitoring without frequent recharging.

Spider Heart Monitor vs. Biocore Pro

Why Biotricity’s Biocore Core Pro Stands Out as the Smarter Choice

While both the Spider Heart Monitor and Biocore Pro offer benefits in continuous heart monitoring, Biocore Pro delivers the highest standard of care through its advanced features, clinical accuracy, and seamless integration with healthcare systems.

• Superior Data Quality: With its 3-lead ECG configuration, Biocore Pro captures more comprehensive heart activity, enabling earlier detection of abnormalities that single-lead or two-lead monitors may miss.
• 24/7 Clinical Access: Biocore Pro transmits data directly to healthcare providers through its dedicated Biocare Diagnostics platform, ensuring prompt response in case of irregularities or emergencies.
• Built for Continuous, Comfortable Use: Biocore Pro’s compact, skin-friendly design allows for extended wear without compromising comfort. Biocore Pro is ideal for patients who need uninterrupted monitoring.
• Integrated, Proactive Care: Biocore Pro isn’t just a device, it’s part of a connected health ecosystem that supports proactive intervention and personalized care plans, giving patients and providers peace of mind.

While the Spider Heart Monitor may be a suitable option for those seeking a lightweight, discreet device for general monitoring, it lacks the clinical-grade performance and connectivity that sets Biocore Pro apart.

For patients and healthcare providers who prioritize safety, accuracy, and comprehensive remote care, Biotricity’s Biocore Pro is the clear choice. To learn more about Biotricity’s Biocore Pro and other cardiac monitoring solutions, visit Biotricity’s official website.

Biotricity stands at the forefront of this revolution in cardiac monitoring, with a mission to make state-of-the-art solutions for proactive management of chronic conditions accessible to all. The Biotricity team in Redwood City, California has been working to create devices that don’t just collect data, but actually make that data meaningful for both patients and healthcare providers.

So What Exactly Is a Cardiac Patch Monitor?

A cardiac patch monitor is a small, lightweight device that sticks directly to your chest to continuously track your heart’s activity. Unlike older, bulky monitors with wires and straps, a cardiac patch monitor is wireless, discreet, and comfortable enough to wear throughout your daily routine. These advanced monitors are designed to catch irregular heart rhythms and other cardiac conditions in real time, even if symptoms come and go. By providing constant, reliable monitoring, a heart patch monitor helps doctors detect potential heart issues early and make informed decisions about your care. Whether you’re at home, at work, or on the go, a cardiac patch monitor offers peace of mind by keeping a close watch on your heart health without interrupting your lifestyle.

Types of Cardiac Tests: Spotlight on Heart Patch Monitors

When it comes to monitoring your heart, there are several study types available—each designed to catch issues at different times and frequencies. A Holter monitor is a classic option, worn for 24–48 hours to record continuous heart activity. If symptoms are less frequent, an extended Holter monitor offers the same function over a longer period, up to 14 days. For even more advanced monitoring, Mobile Cardiac Telemetry (MCT) provides real-time tracking and automatically alerts doctors if it picks up anything unusual. An event monitor is used when symptoms are occasional, recording only when you feel something off or the device detects an irregular rhythm. For long-term cases, an implantable loop recorder is placed under the skin to monitor heart activity for up to three years.

Compared to these options, a cardiac patch monitor or heart patch monitor offers a game-changing balance of convenience and accuracy. These wearable, wire-free monitors provide continuous tracking with the comfort of a simple patch on your chest, making heart health monitoring easier and more accessible than ever.

When Would Someone Need a Cardiac Monitor?

Doctors might suggest a cardiac monitor, including a heart patch monitor, for symptoms like:

• Heart palpitations (when the heart feels like it’s fluttering or racing unexpectedly)
• Unexplained fainting spells
• Dizziness that comes and goes
• Shortness of breath during normal activities
• Chest pain that seems to appear and disappear

One of the biggest challenges with diagnosing heart issues is that they often don’t show up during a quick doctor’s visit. You might feel fine at your appointment but notice troubling symptoms while at home or at work. This is where a cardiac patch monitor or heart patch monitor becomes invaluable. Cardiac patch monitor devices and heart monitor patch devices care capable of capturing these elusive events in real-time, especially because the monitoring period in the outpatient setting is longer. 

The Tech Behind the Heart Patch Monitor: Why Biotricity’s Cardiac Patch Monitor Stands Out 

Modern heart patch monitors are equipped with advanced algorithms capable of detecting irregularities and triggering alerts during critical events. Many connect to smartphone apps, enabling you to log symptoms and track your activity alongside heart data.

Biotricity has transformed cardiac monitoring with products like Biocore Pro, the only connected 3-lead cardiac patch monitor device in the world that doctors prescribe to patients. Then there’s Bioheart, Biotricity’s consumer 3-lead heart monitor that allows users to view heart activity on an app, bringing healthcare technology into people’s everyday lives.

What sets Biotricity apart is their ability to combine powerful hardware with intelligent software. Biotricity’s integrated monitoring platform seamlessly delivers actionable data collected by their cardiac patch monitor devices. This ensures that users get the information they need about their heart health, eliminating any delays in their care management. 

The Bottom Line

Your heart never takes a break—so keeping an eye on it makes perfect sense. Thanks to Biotricity’s advanced heart patch monitor technology, staying on top of your heart health has never been easier. Proactive monitoring today means more moments with loved ones tomorrow, more time doing the things you love, and greater peace of mind knowing your heart is well protected.

Take the American Heart Association’s latest campaign, for example. One story highlighted a marathon runner who felt perfectly healthy but was unknowingly living with an irregular heartbeat. A cardiac monitor patch picked it up during her training, giving her a chance to get the right treatment early. She’s still running strong today! We’ll explore more about the benefits of heart monitoring with a cardiac monitor patch throughout this blog.

What is a Heart Patch Monitor?

A heart patch monitor is a high-tech, wearable device that sticks to your chest and records your heart’s electrical activity. Cardiac monitor patch devices are designed to be unobtrusive so you can go about your everyday life with reassurance that your heart is being monitored, whether you’re working, sleeping, or jogging. Unlike traditional outpatient monitors that only track your heart for 24 to 48 hours, these heart patch monitor devices collect round-the-clock data for up to 30 days. Cardiac monitor patch devices are discreet enough to wear under clothing, and work silently in the background, detecting irregular heartbeats or abnormal rhythms without you having to do anything

How Do These Smart Cardiac Monitor Patch Devices Work?

Your heart has its own electrical system. Each heartbeat starts with an electrical impulse that travels through your heart, making it contract in a specific pattern.

A cardiac monitor patch has built-in sensors that detect these signals and record any unusual patterns, like skipped beats or rapid rhythms. Inside the heart patch monitor are powerful microprocessors, storage memory, and wireless tech that send the data directly to your healthcare provider.

Many heart patch monitor devices also let you press a button when you feel symptoms like lightheadedness or chest discomfort. That way, doctors can correlate what you’re feeling with what your heart is actually doing at that moment.

Who Needs to use a Heart Patch Monitor?

You might benefit from a heart patch monitor if:

• You experience dizziness, fainting, or unexplained fatigue
• You’ve had a stroke with no obvious cause
• Your doctor is adjusting your heart medication and needs ongoing data
• You have a family history of heart rhythm disorders

• What makes these cardiac monitor patch devices special compared to older monitoring methods is how long they can record. Heart patch monitor devices are ideal for capturing elusive heart issues that don’t show up during short-term tests. Traditional monitors typically only record for 24-48 hours. Modern cardiac monitor patch devices can record for up to 30 days, giving doctors a complete picture rather than just a brief snapshot of your heart’s activity.

Living With a Heart Patch

Surprisingly, wearing a cardiac monitor patch is easy and comfortable. A provider applies it in-office, and then you’re free to go about your routine. You can shower, sleep, work, exercise, and do your other normal activities of daily living. Most users even forget the cardiac monitor patch is there!

Many heart patch monitor devices are rechargeable and require no specialized user input. Some heart monitor patch devices connect to an app where you can log medications or symptoms, adding even more insight to the data doctors receive.

What Happens With All That Heart Data?

Once your monitoring period ends, all the data collected by your heart patch monitor is analyzed using advanced software. Cardiologists then review detailed reports that show how your heart’s activity across different times and activities.

This analysis helps your doctor pinpoint the cause of symptoms, detect hidden arrhythmias, or rule out serious conditions, ultimately leading to better, more personalized treatment plans.

The Bottom Line

The cardiac monitor patch represents a major leap forward in heart care. Instead of relying on quick ECG snapshots taken in a doctor’s office, these wearable devices capture the full story of your heart—right in the middle of your real life.

If your doctor recommends a heart patch monitor, it’s a proactive step toward protecting your long-term health. It’s simple, effective, and could be the key to catching heart issues early—before they become something bigger.

Biotricity’s latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care.

REDWOOD CITY, Calif., Mar 12, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times’ list of The Americas’ Fastest-Growing Companies 2025. This recognition highlights Biotricity’s innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges.

Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed revenue growth between 2020 and 2023. During this period, businesses faced significant economic obstacles, including the COVID-19 pandemic, supply chain disruptions, and rising interest rates.

In the face of these challenges, Biotricity has achieved standout growth, fueled by the rising demand for smart remote monitoring solutions. As of 2023, more than 100 million Americans face barriers to accessing essential healthcare services. This underscores the urgent need to increase accessibility to medical care by expanding remote monitoring services. Biotricity is leading this transformation with proprietary technologies that have redefined the standard of continuous remote monitoring for high-risk cardiac patients. Medical providers utilizing Biotricity’s solutions are enabled to deliver faster interventions, improving outcomes for thousands across the U.S. and internationally.

“Being recognized by the Financial Times as one of the fastest-growing companies in the Americas is a tremendous honor and a testament to the dedication of our team,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our mission to revolutionize chronic care management, particularly in the cardiac space, continues to gain momentum, and this milestone validates our approach to innovating in the healthcare landscape.”

The full list and special report will be published by the Financial Times on Tuesday, April 25, 2025, and will be distributed to its U.S. newspaper subscribers and globally on www.ft.com.

For more information about Biotricity and its remote patient monitoring solutions, visit www.biotricity.com or contact investors@biotricity.com.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com

In-office ECGs provide only brief 30-second snapshots of heart activity, making it difficult to detect intermittent heart irregularities. Additionally, traditional Holter monitors typically track heart activity for just 24 to 48 hours which is insufficient for diagnosing conditions that occur sporadically. Since many heart issues are intermittent and may not present symptoms during short monitoring periods, longer, continuous tracking is essential for accurate diagnosis and effective treatment.

Traditional heart monitoring methods, while effective, are often cumbersome, with bulky devices and multiple wires that limit continuous, real-time monitoring. Leading healthcare innovators like Biotricity have transformed this landscape by introducing cutting-edge solutions such as wireless 30-day heart monitor devices. These wireless 30-day heart monitor devices, like Biotricity’s Biocore, not only empower patients with greater control over their heart health but also facilitate timely interventions by healthcare providers when necessary.

The Importance of Real-Time Heart Monitoring

Holter monitors have long been used to detect irregular heart rhythms and diagnose cardiovascular conditions. A Holter monitor is typically prescribed when a doctor needs to evaluate a patient’s heart rhythm over an extended period, beyond what a standard in-office ECG (which lasts only about 30 seconds) can capture. However, their bulky, wired designs can be invasive and limit users activities of daily living, decreasing compliance. Moreover, Since heart issues can be intermittent, a 24-48 hour Holter monitor might not always capture irregularities. As a result, crucial data may be missed, delaying diagnosis and treatment.

Real-time heart monitoring devices address this gap by providing continuous, wireless tracking that ensures accurate, long-term data collection. With advanced wireless wearable devices that monitor the heart 24/7, patients no longer need frequent clinic visits for routine heart assessments. Instead, these wireless 30-day heart monitor devices allow individuals to maintain their regular lifestyle while the device continuously tracks and transmits critical data. If healthcare providers detect even the slightest abnormalities, they can take immediate action to prevent potential complications.

How Biotricity is Empowering Patients

Biotricity has revolutionized cardiac care by offering advanced monitoring solutions that provide patients with continuous access to accurate heart health data. Here’s how our devices empower patients:

1. Wireless 30-Day Heart Monitor for Extended Tracking
   Traditional Holter monitors typically function for only 24 to 48 hours. In contrast, Biotricity’s wireless 30-day heart monitor devices provide continuous tracking for up to 30 days, allowing for a more comprehensive and insightful assessment of heart activity.
2. Seamless Data Transmission for Immediate Action
   Biotricity’s advanced monitoring solutions facilitate continuous data transfer, ensuring that healthcare providers receive immediate updates and can intervene promptly if a heart irregularity is detected.
3. Comfortable, Wireless Design for Everyday Use
   Unlike traditional monitors with restrictive wires and bulky components, Biotricity’s sleek, lightweight design ensures comfort and ease of use, allowing patients to go about their daily routines without disruption. Moreover, Biotricity’s Biocore is a wireless 30-day heart monitor that can be worn in 2 different positions to maximize patient comfort, increasing compliance.
4. AI-Powered Analytics for Precision Monitoring
   Integrating artificial intelligence and cloud-based analytics, Biotricity’s solutions provide actionable insights, detecting even the slightest abnormalities and enabling more personalized, proactive treatment plans.

The Benefits of Real-Time Heart Monitoring for Patients

Biotricity’s innovative solutions provide significant advantages for individuals at risk of heart conditions:

• Early Detection of Heart Conditions: Continuous monitoring over longer durations of time allow for the identification of even minor irregularities, increasing the likelihood of early intervention before a condition becomes life-threatening.
• Improved Patient Engagement: Continuous, reliable data empowers both patients and doctors to actively manage heart health, promoting better outcomes.
• Reduced Clinical Visits: Remote monitoring minimizes the need for frequent clinical visits and reduces risk of needing hospitalization, saving time and reducing healthcare costs.
• More Accurate Diagnoses: Extended monitoring periods provide comprehensive data, ensuring that no abnormalities go undetected.
• Peace of Mind: Patients experience greater confidence and reassurance knowing that their heart health is being constantly monitored, reducing the risk of undetected complications.

The Future of Cardiac Care with Biotricity

As medical technology continues to advance, Biotricity remains dedicated to developing patient-centric solutions that integrate AI, continuous monitoring, and remote accessibility. Our ongoing commitment to innovation, exemplified by our wireless 30-day heart monitor devices, including Biocore, is shaping the future of cardiovascular healthcare—ensuring more accurate, timely, and personalized care.

Conclusion

With the increasing prevalence of cardiovascular diseases, empowering patients with real-time heart monitoring has never been more essential. Continuous tracking solutions, such as Biotricity’s wireless 30-day heart monitor, Biocore, enable individuals to take a proactive role in managing their heart health. By combining AI-driven analytics, advanced technology, and user-friendly designs, Biotricity is at the forefront of transforming how heart disease is monitored, managed, and treated.

For those looking to take control of their heart health, Biotricity offers innovative solutions designed to enhance disease management and improve patient outcomes. Want to learn more? Call us at (800) 590-4155 or visit Biotricity’s website here today.

The Need for Advanced Cardiac Monitoring

Traditional heart monitoring devices, such as Holter monitors, pose significant limitations due to their bulky design and excessive wiring, which restrict mobility and affects patient compliance. While they may be useful for short-term outpatient diagnostics, they are less effective for patients requiring continuous monitoring to detect irregular heart rhythms over extended periods. This is where Biotricity steps in with its state-of-the-art, portable cardiac monitoring solutions. Lets explore more about the benefits of Biotricity’s monitoring medical devices and heart monitor patches, and how Biotricity is reshaping the landscape of cardiac care.

Biotricity’s Role in Transforming Cardiac Health

Biotricity has developed a range of intelligent, AI-powered cardiac monitoring devices, including heart monitor patches like Biocore and Bioheart, which are designed to enhance diagnostic accuracy and patient outcomes. By enabling continuous monitoring, seamless data transmission, cloud-based storage, and AI-driven analysis, Biocore and Bioheart not only improve accuracy but also facilitate early detection and preventive care.

1. Innovative Heart Monitor Patches for Continuous Tracking
   Biotricity’s Biocore and Bioheart are portable heart monitor patches which offer a comfortable, wireless alternative to traditional ECG and Holter devices. Unlike bulky, multi-wired machines, these heart monitor patches provide continuous tracking, allowing physicians to assess heart rhythms over extended periods, up to 30 days, while patients go about their daily activities with ease.
2. AI-Driven Insights for Better Diagnosis
   Biotricity has successfully integrated artificial intelligence into its monitoring devices, enabling quick analysis of vast amounts of cardiac data. This technology helps detect even the slightest irregularities in heart function, empowering healthcare providers to make timely and accurate decisions that can prevent serious complications.
3. Remote Monitoring for Greater Accessibility
   With the rise of telemedicine, remote monitoring has become essential for ensuring widespread access to healthcare. Biotricity’s heart monitor patches, Biocore and Bioheart, provide continuous data transmission to healthcare providers 24/7, eliminating the need for frequent in-person visits. This is particularly beneficial for patients with chronic conditions who require continuous monitoring but face challenges in traveling for regular check-ups.

Key Benefits of Biotricity’s Cardiac Solutions

Biotricity’s innovations in cardiac monitoring benefit both patients and healthcare providers in several ways:

• Early Detection of Heart Conditions: Continuous monitoring with monitoring medical devices enables the early identification of heart irregularities before they escalate into serious health risks, like a heart attack or stroke.
• Enhanced Patient Comfort and Compliance: Lightweight and wireless designs ensure that patients can wear heart monitor patches comfortably while maintaining their daily routines.
• Data-Driven Decision Making: AI-powered analytics and cloud-based storage provide healthcare professionals with actionable insights, eliminating the inefficiencies of raw data analysis. This allows healthcare providers to focus on direct patient care.
• Reduced Hospital Visits: Remote monitoring minimizes the need for frequent hospital visits, saving patients time and reducing healthcare costs.

The Future of Cardiac Health with Biotricity

Medical technology is evolving rapidly, and Biotricity remains committed to making cardiac care more accessible, efficient, and patient-centric. By leveraging AI integration, cloud-based analysis, and remote monitoring solutions, the company is paving the way for a future where heart disease prevention and management are significantly improved.

Through advanced monitoring devices such as Biocore and Bioheart, Biotricity is reshaping how cardiac conditions are tracked, diagnosed, and treated. As the company continues to innovate, its goal remains clear: to revolutionize heart health management and enhance patient outcomes worldwide.

If you’re looking for a reliable, cutting-edge solution for managing heart health, whether as a patient or a healthcare provider, Biotricity’s heart monitoring devices offer one of the best solutions available. Visit our website here or call us at (800) 590-4155 to learn more about how Biotricity can support your cardiac care journey.